Aberrant expression of BARD1 in breast and ovarian cancers with poor prognosis
| العنوان: | Aberrant expression of BARD1 in breast and ovarian cancers with poor prognosis |
|---|---|
| المؤلفون: | Jian-Yu Wu, Karl-Heinz Krause, Marie-Françoise Pelte, Geoffrey J. Laurent, Maria-Adelaide Caligo, Irmgard Irminger-Finger, A. T. Vlastos, Andrea Bianco |
| المساهمون: | Jy, Wu, At, Vlasto, Mf, Pelte, Ma, Caligo, Bianco, A, Kh, Krause, G J., Laurent, I, IRMINGER-FINGER. |
| المصدر: | International journal of cancer. Journal international du cancer International Journal of Cancer, Vol. 118, No 5 (2006) pp. 1215-1226 |
| سنة النشر: | 2005 |
| مصطلحات موضوعية: | CA15-3, Cancer Research, ddc:616.07, Ovarian Neoplasms/ diagnosis/genetics/ metabolism/pathology, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Aged, 80 and over, Ovarian Neoplasms, 0303 health sciences, BRCA1 Protein, Middle Aged, Prognosis, Gene Expression Regulation, Neoplastic, ovarian cancer, Oncology, 030220 oncology & carcinogenesis, Female, Carcinoma, Non-Small-Cell Lung/genetics/metabolism, Adult, Mutation/genetics, Ubiquitin-Protein Ligases, Tumor Suppressor Proteins/genetics/ metabolism, Breast Neoplasms, Ubiquitin-Protein Ligases/genetics/ metabolism, Biology, 03 medical and health sciences, breast cancer, Breast cancer, BARD1, medicine, Carcinoma, Humans, Breast Neoplasms/ diagnosis/genetics/ metabolism/pathology, Lung cancer, Tumor Suppressor Protein p53/metabolism, 030304 developmental biology, Aged, Tumor Suppressor Proteins, Cancer, BRCA1, medicine.disease, lung cancer, Cancer cell, Mutation, Cancer research, BRCA1 Protein/genetics, Tumor Suppressor Protein p53, Ovarian cancer |
| الوصف: | Mutations in tumor-suppressor gene BARD1 have been found in inherited and spontaneous breast, ovarian and uterine cancers. BARD1 plays a critical role in DNA repair and ubiquitination as binding partner of BRCA1, with which it colocalizes to nuclear dots. Independently of BRCA1, BARD1 can induce p53-dependent apoptosis in response to genotoxic stress. Therefore, BARD1 or p53 might be defective in cancer cells spared from apoptosis. We investigated BARD1 and p53 expression in ovarian, breast and non-small-cell lung cancers. BARD1 expression was highly upregulated and cytoplasmic in most cancer cells, while weak nuclear staining was observed in the surrounding normal tissue. Maximal BARD1 expression was associated with the most malignant ovarian cancer, clear cell carcinoma. In breast cancer, BARD1 expression was correlated with poor differentiation and large tumor size, established factors of poor prognosis, as well as short disease-free survival. In contrast to breast and ovarian cancers, no correlation of BARD1 expression with either grade or stage could be determined for lung cancer. RT-PCR, performed on 10 ovarian cancers, revealed absence of the 5' portion of the BARD1 transcript in 7 tumors, and sequencing of the remaining 3 identified a missense mutation (A1291G) resulting in an amino acid change of glutamine 406 to arginine. These data suggest that genetic and epigenetic changes might lead to elevated cytoplasmic expression of BARD1 and that cytoplasmic BARD1 might be a poor prognostic factor for breast and ovarian cancers. |
| تدمد: | 0020-7136 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03f7aeb2d51875b8bb8e3d4336f5a509Test https://pubmed.ncbi.nlm.nih.gov/16152612Test |
| حقوق: | RESTRICTED |
| رقم الانضمام: | edsair.doi.dedup.....03f7aeb2d51875b8bb8e3d4336f5a509 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 00207136 |
|---|